Italia Markets closed

Genetic Technologies Limited (0A4N.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,9100-0,4154 (-17,86%)
Alla chiusura: 05:30PM BST
Schermo intero
Chiusura precedente2,3254
Aperto0,0000
Denaro0,0000 x N/D
Domanda0,0000 x N/D
Min-Max giorno0,0000 - 0,0000
Intervallo di 52 settimane
Volume165
Media Volume449
CapitalizzazioneN/D
Beta (mensile su 5 anni)0,44
Rapporto PE (ttm)N/D
EPS (ttm)-0,6000
Prossima data utili29 ago 2024 - 02 set 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    GTG Signs Precision Medicine Pilot with Australia’s Largest Private Hospital Network

    GeneType and Gold Coast Hospital Simon Morriss - Genetic Technologies Ltd CEO and Michelle Ferrari Cestari - Gold Coast Hospital Research Manager GTG CEO, Simon Morriss, is pleased to announce collaboration with Gold Coast Hospital Simon Morriss, Genetic Technologies CEO's Statement MELBOURNE, Australia, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease is pl

  • GlobeNewswire

    Breakthrough: GeneType for Pancreatic Cancer, Melanoma, and Atrial Fibrillation Cleared for Australian Release

    Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) Expands Reach of Revolutionary geneType Multi-Risk Test in Australia: A major advancement towards preventative Healthcare MELBOURNE, Australia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (GTG), a pioneering global leader in genomics-based tests focused on health, wellness, and the battle against serious diseases, proudly announces a groundbreaking development. The expanded geneType Multi-Risk Test is now readily accessibl

  • GlobeNewswire

    Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report® on Bloomberg TV

    MELBOURNE, Australia, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to advise that RedChip Companies will air interviews with Genetic Technologies Limited (Nasdaq: GENE) and 60 Degrees Pharmaceuticals (60P) (NASDAQ: SXTP) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 2, at 7 p.m. Eas